Colorectal cancer (CRC) is a prevalent and deadly disease worldwide. Around 1.9 million new cases and over 903,000 deaths were estimated in 2022. 1 In the United States, it has been projected that by ...

There were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2020. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

The article by Arnold et al titled “Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study” (J Glob Oncol 10.1200/GO-25-00018) ...

Ten sponsors contributed 67 analyzable trials with N = 12,000 US-based participants. Enrollment odds decreased 49% in the initial wave (odds ratio [OR], 0.51 [95% CI, 0.30 to 0.86], P = .01) but ...

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate ...

The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy ...

Cervical cancer remains a leading cause of cancer-related death among women globally, despite the availability of effective prevention through human papillomavirus (HPV) vaccination and HPV-based ...

Colorectal cancer (CRC) is the third most common cancer worldwide, responsible for approximately 10% of all cancer cases and is the second leading cause of cancer-related deaths according to WHO. 1 ...

A preference-based multisite randomized comparative effectiveness trial design with broad pragmatic inclusion criteria was used. Participants with a preference for either MBCR or TCQ received their ...

More recently, the use of neoadjuvant therapies has demonstrated benefit in patients with resectable stage III/IV melanoma. SWOG 1801, a phase II randomized trial, examined perioperative (neoadjuvant ...

For the purpose of this paper, we define oncology rehabilitation as services provided by licensed medical providers (eg, physical or occupational therapists, physical medicine and rehabilitation ...